Comvita, which sells products based on the health and medical benefits of honey, posted a 7.4% drop in first-half profit, saying a shortage of Manuka honey after an inclement 2012 summer constrained sales growth and margins.
Profit fell to $2.39 million, or 7.95 cents a share, in the six months ended September 30, from $2.58 million, or 8.92 cents a year earlier, the Te Puke-based company says in a statement. Sales climbed to $45.4 million from $41.8 million.
The year-on-year result would have been a gain in profit but the year-earlier numbers were restated for what Comvita says were errors in the accounting treatment of operational costs in its apiary business. The amendments do not change the full-year result of $8.2 million, a figure the company expects to better in the current year.
"Comvita historically has a year of two halves, with the second-half year sales and profits significantly stronger than the first half," chairman Neil Craig says. "We expect this to be the case again this financial year as Asian sales continue to grow strongly."
Trading activity in China, South Korea and Hong Kong, where Comvita mainly operates a direct-to-consumer retail business, "has been especially strong", the company says. "Still, in non-Asian markets such as Australia and the UK the trading environment has been relatively tough.
"The other factor that has been a constraint on sales growth and margins during this first half year is the short supply of our key ingredient, manuka honey," it says.
"The honey crop from last summer was well below average, due to generally inclement weather during the summer of 2011-12, resulting in a sharp increase in the purchase price for new season honey."
To limit the impact of price fluctuations, the company is seeking direct ownership of more of its honey supplies. It now has four apiaries in the North Island, which supply about a third of its honey requirements.
The company will pay a first-half dividend of 4 cents a share. It did not pay a dividend in the first half of last year. Its shares last traded at $3.70 and have gained 50% this year.
This time last year it rejected a $2.50 a share takeover offer from Cerebos New Zealand, a unit of Singapore-listed Cerebos Pacific.
"We remain confident that both top line and bottom line growth can be achieved for this fiscal year and beyond," chief executive Brett Hewlett says.
This article is tagged with the following keywords. Find out more about MyNBR Tags
- iPredict closing down due to money laundering risk
- Pumpkin Patch affirms guidance for weaker 2016 earnings, shares drop
- Xero directors Drury, Winkler and Morgan cash in on 35% share price rally
- Serco's prison report challenge: Hide and Davis go head-to-head
- Sir Ralph Norris spells out reasons for Fonterra board departure
Most listened to
- “A very ballsy thing to do” – Rodney Hide and Kelvin Davis discuss Serco’s response to Correction’s Mt Eden Prison report
- “The response from shareholders has been overwhelming” — A2 Corporation chief executive Geoff Babidge
- Greg Gent says a board of 13 people is "prehistoric"
- Arvida CEO Bill McDonald on his company's half-year net profit
- Lance Wiggs on the future of food exports
- Auckland Councillor Chris Darby on the Council's alternative funding report
- Nevil Gibson discusses his latest Editor's Insight on oil prices
- Campbell Gibson, Nick Grant and Chelsea Armitage chat about the inner workings of New Zealand media
- Paul Brislen discusses the 'snake oil' sales tactics of SalesConcepts
- Fonterra chief executive Theo Spierings reveals his ambitious China plan
- UDC Finance chief executive Wayne Percival talks about the company's profit
- Hamish McNicol discusses the latest court stories